RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.

By PR Newswire7 days ago

TEL AVIV, Israel and RALEIGH, NC, Feb. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill“ or the “Company“), a specialty biopharmaceutical company, today announced its plans to expand the Company's global Phase 2/3 study of opaganib[1] in patients with severe...

Continue read on prnewswire.com